What are your outpatient surveillance strategies (biomarkers, imaging, symptoms) to monitor response to treatment for ATTR amyloidosis with cardiac involvement?
How do you determine duration of therapy for Tafamidis, or is it continued indefinitely for the patient?
Answer from: at Academic Institution
I continue it indefinitely. Limited survival data shows a beneficial effect for at least 5 years with survival on the drug of 55% compared to 37% on placebo.Elliot et al., PMID 34923848However, if patients deteriorate dramatically on therapy and are class IV NYHA, I discuss with patients and family ...
Sign in or Register to read more